Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe. The company primarily focuses its research and development on the treatment for hepatitis C virus. The company develops nucleoside/nucleotide polymerase inhibitors, including IDX184, a liver-targeted nucleotide prodrug candidate, which is in phase IIa clinical trial; and IDX102 that completed late-stage preclinical development. It also develops IDX375, a novel palm-binding polymerase inhibitor that is in phase I program; IDX320, a protease inhibitor candidate, which is in phase I healthy volunteer clinical study; and NS5A inhibitors. In addition, the company licensed its telbivudine (Tyzeka/Sebivo), a drug for the treatment of hepatitis B virus, to Novartis Pharma AG; and GSK2248761, a drug candidate from the class of compounds known as non-nucleoside reverse transcriptase inhibitors (NNRTIs), for the treatment of human immunodeficiency virus type 1 and acquired immune deficiency syndrome to GlaxoSmithKline. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Additional discussion on IDIX, its competitors,
and the industry in which it operates may be
found on the Biotech Values board.
IDIX Investor Relations